<DOC>
	<DOCNO>NCT02386306</DOCNO>
	<brief_summary>This Phase 1b , multi-center , randomize , double-blind , placebo-controlled study design evaluate safety , tolerability , pharmacokinetics GC021109 subject mild moderate Alzheimer 's Disease ( determined 2011 National Institute Aging- Alzheimer 's Association [ NIA-AA ] criterion Mini Mental State Examination [ MMSE ] ) . The Investigator , study site staff , ( exception designate pharmacist/pharmacy technician ) study subject blind randomize study medication assignment database lock . Treatment assignment may unblinded select pre-authorized individual involve safety PK data review order accurately determine proceed dose escalation .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , PK Multiple Ascending Doses GC021109 Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Male female subject age 5585 year , inclusive , time informed consent . 2 . Subjects diagnose mild moderate AD determine follow : 1 . Diagnosis probable AD accord 2011 NIAAA criterion 2 . MMSE ( use serial 7 's ) score 1226 screening ( Mild define 2026 Moderate define 1219 ) 3 . Documentation clinic note mild/moderate AD 3 . If AD therapy , stable dose least 3 month prior screen . 4 . All male subject must practice effective contraception study . Females childbearing potential must use medically accepted form birth control , unless postmenopausal &gt; 1 year ( document elevate folliclestimulating hormone [ FSH ] ) surgically sterile . All female childbearing potential must negative serum pregnancy test ( human chorionic gonadotropin beta [ hCGβ ] ) screen negative urine pregnancy test Day 1 predose . 5 . Body mass index ( BMI ) 18 35 kg/m2 , inclusive , screen . 6 . Must eligible caregiver ( spend minimum 10 hour per week subject ) available duration study serve subject 's designee . Caregiver must willing comply study procedure . 7 . Caregiver must sign caregiver ICF nature risk study participation fully explain . 8 . Patients capable , accord Investigator , patient 's legally authorize representative , must sign patient ICF nature risk study participation fully explain . 9 . Patients capable provide assent capable signing ICF , accord Investigator , provide assent study participation . 1 . Patients sign ICF require provide separate assent . 2 . Patients capable provide assent still allow participate provide patient 's legally authorize representative agrees participation . Investigators must document reason patient unable provide assent maintain documentation consent/assent document . 10 . Must able comply study requirement restriction duration study . 11 . Nonsmoker nontobacco user minimum 3 month prior screen duration study . 12 . Ability swallow capsule . 1 . MRI finding inconsistent AD within previous 12 month . All subject must MRI within previous 12 month eligible . 2 . History current evidence clinically significant cardiac , endocrinologic , hematologic , hepatobiliary , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator . 3 . History cancer within past five year ( exclude nonmelanoma skin cancer ) . 4 . Active suicidal ideation report Columbia Suicide Severity Rating Scale ( C SSRS ) screening . 5 . Clinically significant abnormal laboratory test value screen ( determined Investigator ) , include : 1. value alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 1.5 time upper limit reference range 2. value total direct bilirubin 1.5 time upper limit reference range 3. estimate glomerular filtration rate &lt; 85ml/min/1.73m2 . 6 . Subjects QTc ≥450 msec male ≥470 msec female screen . 7 . Participation another clinical trial treatment investigational agent within 30 day 5 halflives , whichever longer , prior Day 1 . 8 . Subjects body weight &gt; 120 kg screening . 9 . History alcohol drug abuse dependence within 12 month screen determined Investigator . 10 . Clinically significant infection within 3 month screen determined Investigator . 11 . Any condition , opinion Investigator , would make subject unsuitable enrollment could interfere subject 's participation completion study . 12 . Positive urine screen prohibit drug ( cocaine , cannabinoids , nicotine [ urine cotinine detection mechanism nicotine ] , opiates , barbiturate , amphetamine , benzodiazepine ) positive alcohol Breathalyzer Day 1 . 13 . Positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) screening . 14 . Known suspected hypersensitivity idiosyncratic reaction study medication component thereof . 15 . Has donate blood within 3 month screen plan donate blood within 3 month study completion .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>